Neurologisches Management von Patienten mit Morbus Fabry

Zusammenfassung

Morbus Fabry ist eine X-chromosomal vererbte lysosomale Speichererkrankung, bei der es durch einen Defekt im GLA-Gen zu einer verminderten Aktivität des Enzyms α-Galaktosidase A kommt. Es resultiert ein verminderter Abbau von Glykosphingolipiden, die in den Lysosomen verschiedener Gewebe akkumulieren und somit zu einer Erkrankung multipler Organsysteme führen. Neben der kardialen und renalen Manifestation sind v. a. die neurologischen Komplikationen des Morbus Fabry für die reduzierte Lebenserwartung und die verminderte Lebensqualität verantwortlich. Ischämische Schlaganfälle, eine zerebrale Mikroangiopathie und neuropathische Beschwerden in Form von paroxysmalen Brennschmerzen sind zudem oft die häufigsten und frühesten Symptome, weshalb dem Neurologen sowohl bei der Diagnosestellung als auch beim klinischen Management behandelter Fabry-Patienten eine entscheidende Rolle zukommt. Trotz der mittlerweile etablierten Enzymersatztherapie ist eine symptomatische Therapie und regelmäßige Kontrolle der neurologischen Manifestationen notwendig und für die Lebensqualität der Patienten essenziell. Deshalb sind regelmäßige fachneurologische Untersuchungen innerhalb eines interdisziplinären Therapiekonzepts des Morbus Fabry von großer Bedeutung. Dieser Beitrag gibt einen Überblick über die symptomatischen Behandlungsstrategien und das sinnvolle klinische Management von Fabry-Patienten auf neurologischem Fachgebiet.

Abstract

Fabry disease (FD) is an X-linked lysosomal storage disorder characterised by deficient activity of the enzyme alpha-galactosidase A, resulting in an accumulation of glycosphingolipids in the lysosomes of various tissues, which leads to an involvement of multiple organ systems. The life span in Fabry patients is shortened and quality of life is significantly decreased, mainly due to heart failure, renal dysfunction and the neurological symptoms. Premature strokes, cerebral white matter lesions, and neuropathic symptoms – typically experienced as episodes of severe burning pain – are very common and early symptoms of the disease. Therefore, neurologists play a decisive role in clinical diagnostics and monitoring of Fabry patients. Although an enzyme replacement therapy is available since 2001, adjuvant symptomatic treatment and regular monitoring of neurological manifestations are still required and remain crucial factors for an improvement of patients quality of life. Thus, the neurological management of Fabry patients is one of the mainstays of the interdisciplinary care and management efforts. Here we provide an overview of the neurological aspects of clinical management and adjuvant treatment strategies in patients with Fabry disease.

Schlüsselwörter

Morbus Fabry - lysosomale Speichererkrankungen - klinisches Management

Keywords

Fabry disease - lysosomal storage diseases - clinical management

Literatur

• 1 Desnick R J, Brady R, Barranger J. et al . Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.  Ann Intern Med. 2003;  138 338-346
• 2 Eng C M, Fletcher J, Wilcox W R. et al . Fabry disease: baseline medical characteristics of a cohort of 1765-males and females in the Fabry Registry.  J Inherit Metab Dis. 2007;  30 184-192
• 3 Zarate Y A, Hopkin R J. Fabry's disease.  Lancet. 2008;  372 1427-1435
• 4 MacDermot K D, Holmes A, Miners A H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males.  J Med Genet. 2001;  38 750-760
• 5 MacDermot K D, Holmes A, Miners A H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females.  J Med Genet. 2001;  38 769-775
• 6 Fellgiebel A, Muller M J, Ginsberg L. CNS manifestations of Fabry's disease.  Lancet Neurol. 2006;  5 791-795
• 7 Meikle P J, Hopwood J J, Clague A E. et al . Prevalence of lysosomal storage disorders.  JAMA. 1999;  281 249-254
• 8 Chimenti C, Pieroni M, Morgante E. et al . Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.  Circulation. 2004;  110 1047-1053
• 9 Nakao S, Kodama C, Takenaka T. et al . Fabry disease: detection of undiagnosed hemodialysis patients and identification of a „renal variant” phenotype.  Kidney Int. 2003;  64 801-807
• 10 Tanaka M, Ohashi T, Kobayashi M. et al . Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients.  Clin Nephrol. 2005;  64 281-287
• 11 Rolfs A, Bottcher T, Zschiesche M. et al . Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.  Lancet. 2005;  366 1794-1796
• 12 Cybulla M, Walter K, Neumann H P. et al . Fabry disease: demographic data since introduction of enzyme replacement therapy.  Dtsch Med Wochenschr. 2007;  132 1505-1509
• 13 Grau A J, Schwaninger M, Goebel H H. et al . Fabry's disease: new therapeutic options for this lysosomal storage disorder.  Nervenarzt. 2003;  74 489-496
• 14 Mehta A, Ricci R, Widmer U. et al . Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.  Eur J Clin Invest. 2004;  34 236-242
• 15 Ries M, Ramaswami U, Parini R. et al . The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents.  Eur J Pediatr. 2003;  162 767-772
• 16 MacDermot J, MacDermot K D. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options.  Eur J Pharmacol. 2001;  429 121-125
• 17 Schiffmann R, Kopp J B, Austin H A. et al . Enzyme replacement therapy in Fabry disease: a randomized controlled trial.  JAMA. 2001;  285 2743-2749
• 18 Eng C M, Guffon N, Wilcox W R. et al . Safety and efficacy of recombinant human α-galactosidase A – replacement therapy in Fabry's disease.  N Engl J Med. 2001;  345 9-16
• 19 Gadoth N, Sandbank U. Involvement of dorsal root ganglia in Fabry's disease.  J Med Genet. 1983;  20 309-312
• 20 Gemignani F, Marbini A, Bragaglia M M. et al . Pathological study of the sural nerve in Fabry's disease.  Eur Neurol. 1984;  23 173-181
• 21 Lacomis D, Roeske-Anderson L, Mathie L. Neuropathy and Fabry's disease.  Muscle Nerve. 2005;  31 102-107
• 22 Toyooka K, Said G. Nerve biopsy findings in hemizygous and heterozygous patients with Fabry's disease.  J Neurol. 1997;  244 464-468
• 23 Ramaswami U. Fabry disease during childhood: clinical manifestations and treatment with agalsidase alfa.  Acta Paediatr Suppl. 2008;  97 38-40
• 24 Weidemann F, Strotmann J M, Breunig F. et al . Misleading terms in Anderson-Fabry disease.  Eur J Clin Invest. 2008;  38 191-196
• 25 Hilz M J, Stemper B, Kolodny E H. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients.  Pain. 2000;  84 361-365
• 26 Moller A T, Feldt-Rasmussen U, Rasmussen A K. et al . Small-fibre neuropathy in female Fabry patients: reduced allodynia and skin blood flow after topical capsaicin.  J Peripher Nerv Syst. 2006;  11 119-125
• 27 Torvin M A, Winther B F, Feldt-Rasmussen U. et al . Functional and structural nerve fiber findings in heterozygote patients with Fabry disease.  Pain. 2009;  145 237-245
• 28 Hilz M J, Brys M, Marthol H. et al . Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.  Neurology. 2004;  62 1066-1072
• 29 Schiffmann R, Floeter M K, Dambrosia J M. et al . Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.  Muscle Nerve. 2003;  28 703-710
• 30 Baron R, Birklein F, Maier C. et al . Therapie neuropathischer Schmerzen. In: Diener HC, Putzki N, Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Thieme 2008: 630-639
• 31 Yamamoto K, Sobue G, Iwase S. et al . Possible mechanism of anhidrosis in a symptomatic female carrier of Fabry's disease: an assessment by skin sympathetic nerve activity and sympathetic skin response.  Clin Auton Res. 1996;  6 107-110
• 32 Kang W H, Chun S I, Lee S. Generalized anhidrosis associated with Fabry's disease.  J Am Acad Dermatol. 1987;  17 883-887
• 33 Kato H, Sato K, Hattori S. et al . Fabry's disease.  Intern Med. 1992;  31 682-685
• 34 Banikazemi M, Ullman T, Desnick R J. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.  Mol Genet Metab. 2005;  85 255-259
• 35 Grewal R P. Stroke in Fabry's disease.  J Neurol. 1994;  241 153-156
• 36 Crutchfield K E, Patronas N J, Dambrosia J M. et al . Quantitative analysis of cerebral vasculopathy in patients with Fabry disease.  Neurology. 1998;  50 1746-1749
• 37 Fellgiebel A, Muller M J, Mazanek M. et al . White matter lesion severity in male and female patients with Fabry disease.  Neurology. 2005;  65 600-602
• 38 Mitsias P, Levine S R. Cerebrovascular complications of Fabry's disease.  Ann Neurol. 1996;  40 8-17
• 39 Brown A, Milne J A. Diffuse angiokeratoma: report of two cases with diffuse skin changes, one with neurological symptoms and splenomegaly.  Glasgow Med J. 1952;  33 361-367
• 40 Mehta A, Ginsberg L. Natural history of the cerebrovascular complications of Fabry disease.  Acta Paediatr. 2005;  94 (Suppl.) 24-27
• 41 Grewal R P, McLatchey S K. Cerebrovascular manifestations in a female carrier of Fabry's disease.  Acta Neurol Belg. 1992;  92 36-40
• 42 Buechner S, Moretti M, Burlina A P. et al . Central nervous system involvement in anderson-fabry disease: A clinical and MRI retrospective study.  J Neurol Neurosurg Psychiatry. 2008;  79 1249-1254
• 43 Wang R Y, Lelis A, Mirocha J. et al . Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life.  Genet Med. 2007;  9 34-45
• 44 Cabrera-Salazar M A, O'Rourke E, Charria-Ortiz G. et al . Radiological evidence of early cerebral microvascular disease in young children with Fabry disease.  J Pediatr. 2005;  147 102-105
• 45 Tondel C, Laegreid L M, Hirth A. et al . [Intravenous enzyme substitution therapy in children with Fabry's disease].  Tidsskr Nor Laegeforen. 2003;  123 3388-3390
• 46 Albrecht J, Dellani P R, Muller M J. et al . Voxel based analyses of diffusion tensor imaging in Fabry disease.  J Neurol Neurosurg Psychiatry. 2007;  78 964-969
• 47 Fellgiebel A, Mazanek M, Whybra C. et al . Pattern of microstructural brain tissue alterations in Fabry disease: a diffusion-tensor imaging study.  J Neurol. 2006;  253 780-787
• 48 Fellgiebel A, Albrecht J, Dellani P R. et al . Quantification of brain tissue alterations in Fabry disease using diffusion-tensor imaging.  Acta Paediatr. 2007;  96 (Suppl.) 33-36
• 49 Fellgiebel A. Stroke and brain structural alterations in Fabry disease.  Clin Ther. 2007;  29 (Suppl. A) S9-10
• 50 Gunning-Dixon F M, Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review.  Neuropsychology. 2000;  14 224-232
• 51 Miranda B, Madureira S, Verdelho A. et al . Self-perceived memory impairment and cognitive performance in an elderly independent population with age-related white matter changes.  J Neurol Neurosurg Psychiatry. 2008;  79 869-873
• 52 Ross E D, Hansel S L, Orbelo D M. et al . Relationship of leukoaraiosis to cognitive decline and cognitive aging.  Cogn Behav Neurol. 2005;  18 89-97
• 53 Baezner H, Blahak C, Poggesi A. et al . Association of gait and balance disorders with age-related white matter changes: the LADIS study.  Neurology. 2008;  70 935-942
• 54 De Reuck J, Decoo D, Boon P. et al . Late-onset epileptic seizures in patients with leukoaraiosis: a positron emission tomographic study.  Eur Neurol. 1996;  36 20-24
• 55 Grewal R P. Psychiatric disorders in patients with Fabry's disease.  Int J Psychiatry Med. 1993;  23 307-312
• 56 Mohanraj R, Leach J P, Broome J C. et al . Neurological presentation of Fabry's disease in a 52 year old man.  J Neurol Neurosurg Psychiatry. 2002;  73 340-342
• 57 Mendez M F, Stanley T M, Medel N M. et al . The vascular dementia of Fabry's disease.  Dement Geriatr Cogn Disord. 1997;  8 252-257
• 58 Muller M J, Muller K M, Dascalescu A. et al . [Psychiatric and neuropsychological signs and symptoms in patients with fabry disease: literature review].  Fortschr Neurol Psychiatr. 2005;  73 687-693
• 59 Cox T M. Metabolic disorders: lysosomal storage disease. In: Warrell DA, Cox TM, Firth JD, Benz EJ, eds Oxfort Textbook of Medicine. Oxfort, UK; Oxfort University Press 2003: 119-120
• 60 Lyon M F. Gene action in the X-chromosome of the mouse (Mus musculus L.).  Nature. 1961;  190 372-373
• 61 Morrone A, Cavicchi C, Bardelli T. et al . Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers.  J Med Genet. 2003;  40 e103
• 62 Sunder-Plassmann G, Födiger M. Diagnosis of fabry disease: the role of screening and case-finding studies. In: Mehta A, Beck M, Sunder-Plassmann G, eds Fabry Disease: Perspectives from 5 Years of FOS. 2006: 163-168
• 63 Kuller Jr L H, Longstreth W T, Arnold A M. et al . White matter hyperintensity on cranial magnetic resonance imaging: a predictor of stroke.  Stroke. 2004;  35 1821-1825
• 64 Vermeer S E, Hollander M, van Dijk E J. et al . Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study.  Stroke. 2003;  34 1126-1129
• 65 Yamauchi H, Fukuda H, Oyanagi C. Significance of white matter high intensity lesions as a predictor of stroke from arteriolosclerosis.  J Neurol Neurosurg Psychiatry. 2002;  72 576-582
• 66 Fellgiebel A, Keller I, Marin D. et al . Diagnostic utility of different MRI and MR angiography measures in Fabry disease.  Neurology. 2009;  72 63-68
• 67 Hilz M J. Evaluation of peripheral and autonomic nerve function in Fabry disease.  Acta Paediatr. 2002;  91 (Suppl.) 38-42
• 68 Rolke R, Baron R, Maier C. et al . Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values.  Pain. 2006;  123 231-243
• 69 Maag R, Binder A, Maier C. et al . Detection of a characteristic painful neuropathy in Fabry disease: a pilot study.  Pain Med. 2008;  9 1217-1223
• 70 Dutsch M, Marthol H, Stemper B. et al . Small fiber dysfunction predominates in Fabry neuropathy.  J Clin Neurophysiol. 2002;  19 575-586
• 71 Luciano C A, Russell J W, Banerjee T K. et al . Physiological characterization of neuropathy in Fabry's disease.  Muscle Nerve. 2002;  26 622-629
• 72 Sommer C. Skin biopsy as a diagnostic tool.  Curr Opin Neurol. 2008;  21 563-568
• 73 Robbins J, Redline S, Ervin A. et al . Associations of sleep-disordered breathing and cerebral changes on MRI.  J Clin Sleep Med. 2005;  1 159-165
• 74 Jardim L, Vedolin L, Schwartz I V. et al . CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy.  J Inherit Metab Dis. 2004;  27 229-240
• 75 Jardim L B, Aesse F, Vedolin L M. et al . White matter lesions in Fabry disease before and after enzyme replacement therapy: a 2-year follow-up.  Arq Neuropsiquiatr. 2006;  64 711-717
• 76 Wilcox W R, Banikazemi M, Guffon N. et al . Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.  Am J Hum Genet. 2004;  75 65-74
• 77 Lockman L A, Hunninghake D B, Krivit W. et al . Relief of pain of Fabry's disease by diphenylhydantoin.  Neurology. 1973;  23 871-875
• 78 Gordon K E, Ludman M D, Finley G A. Successful treatment of painful crises of Fabry disease with low dose morphine.  Pediatr Neurol. 1995;  12 250-251
• 79 Diener H C, Allenberg J R, Bode C. et al . Primär- und Sekundärprävention der zerebralen Ischämie. In: Diener HC, Putzki N, Hrsg Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart; Springer 2008
• 80 Eng C M, Germain D P, Banikazemi M. et al . Fabry disease: guidelines for the evaluation and management of multi-organ system involvement.  Genet Med. 2006;  8 539-548